Welcome to our dedicated page for Prestige Consumer Healthcare news (Ticker: PBH), a resource for investors and traders seeking the latest updates and insights on Prestige Consumer Healthcare stock.
Prestige Consumer Healthcare Inc. (NYSE: PBH) is a leading provider of over-the-counter (OTC) healthcare products, serving consumers across North America and globally in markets such as Australia, New Zealand, and Asia. The company boasts a diverse portfolio of trusted brands that include household names like Clear Eyes, DenTek, Summer's Eve, Monistat, BC, Goody's, and Dramamine, among others. With a focus on product innovation and quality, Prestige Consumer Healthcare aims to enhance the lives of its customers worldwide.
Founded on the principles of trust and reliability, Prestige Consumer Healthcare is recognized as the largest independent provider of OTC healthcare products in North America. The company's success is attributed to its ability to remain agile while maintaining detailed attention to its extensive range of product offerings. This is reflected in the company's consistent efforts to improve and create products that align with the ever-evolving needs of consumers and their families.
Recent achievements for Prestige Consumer Healthcare include strong financial performances, as evidenced by their second quarter fiscal 2024 results. The company reported revenues of $286.3 million and a net income of $53.6 million, highlighting a robust growth in earnings per share. This was driven by the diverse and leading portfolio of brands, along with broad distribution and a solid financial model. Strong performances in categories such as Cough & Cold and Ear & Eye Care contributed significantly to these results.
In terms of financial health, Prestige Consumer Healthcare continues to demonstrate strong cash flow generation. For the second quarter of fiscal 2024, the company reported net cash provided by operating activities at $62.5 million and a non-GAAP free cash flow of $59.5 million. Debt reduction and disciplined capital deployment remain key priorities, with the company reducing its net debt to approximately $1.2 billion and achieving a leverage ratio of 3.0x.
Partnerships and global reach are also integral to Prestige Consumer Healthcare's strategy. The company generates around 85% of its total revenue from North America, with the remaining sales coming from international markets. Key brands such as Hydralyte in Australia and niche consumer health products in other regions underscore the company's global presence and commitment to meeting diverse healthcare needs.
Looking ahead, Prestige Consumer Healthcare is optimistic about its growth prospects, reaffirming its fiscal 2024 outlook with expectations of continued sales and earnings growth. The company remains well-positioned to create long-term shareholder value through stable organic growth and strategic capital allocation.
FAQ
What is the current stock price of Prestige Consumer Healthcare (PBH)?
What is the market cap of Prestige Consumer Healthcare (PBH)?
What does Prestige Consumer Healthcare Inc. do?
Where does Prestige Consumer Healthcare generate most of its revenue?
What recent financial results has Prestige Consumer Healthcare reported?
How is Prestige Consumer Healthcare managing its debt?
What are some of the key brands under Prestige Consumer Healthcare?
What is the company's approach to product innovation?
What is the company's outlook for the future?
How does Prestige Consumer Healthcare support its global operations?
What is the company's financial strategy?
How can investors access the company's financial updates?
